2026 Global: Cancer Diagnostics Market-Competitive Review (2032) report
Description
The 2026 Global: Cancer Diagnostics Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer diagnostics market by geography and historical trend. The scope of the report extends to sizing of the cancer diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann‑La Roche (Roche) leads the cancer diagnostics market with an extensive portfolio spanning tissue diagnostics, molecular assays, next‑generation sequencing, and companion diagnostics, and its diagnostics division is a market cornerstone for oncology testing worldwide. Illumina anchors genomics‑based cancer diagnostics through high‑throughput next‑generation sequencing platforms that enable comprehensive tumor profiling and support many liquid biopsy and precision‑medicine workflows. Guardant Health is a leader in ctDNA liquid biopsy for non‑invasive tumor genomic profiling and monitoring, with products like Guardant360 that have advanced real‑time treatment selection and minimal‑residual‑disease assessment. Thermo Fisher Scientific supplies a broad range of oncology‑relevant instruments, reagents, and sequencing solutions that support clinical labs and biopharma across molecular diagnostics, NGS, and companion diagnostics. Abbott Laboratories contributes immunoassays, molecular diagnostics, and point‑of‑care testing for key cancer biomarkers, maintaining a strong presence in clinical screening and companion testing.
Siemens Healthineers and GE Healthcare are major imaging and diagnostic systems providers whose platforms—ranging from advanced PET/CT and MRI scanners to laboratory automation—are central to cancer detection, staging, and therapy monitoring in clinical practice. Danaher Corporation, through its diagnostics subsidiaries (including Beckman Coulter and Leica Biosystems), offers immunoassays, flow cytometry, histopathology instruments, and molecular platforms that address multiple oncology testing needs across hospital and reference labs. Roche‑competitor Agilent Technologies and Bio‑Rad Laboratories supply critical instrumentation and assays used in molecular oncology research and diagnostics: Agilent for genomic and proteomic analytical systems and Bio‑Rad for highly sensitive ddPCR and other molecular tools used in ctDNA and mutation detection workflows. Qiagen provides sample‑to‑answer molecular diagnostic kits, nucleic acid extraction technologies, and companion‑diagnostic assays that facilitate robust molecular testing pipelines for oncology patients.
Several specialized and emerging players round out the top ten by driving niche innovation and clinical translation in cancer diagnostics. Exact Sciences focuses on population screening and molecular assays for cancer detection, notably colorectal cancer screening tests that combine molecular markers with clinical workflows. Myriad Genetics develops hereditary cancer risk assays and gene‑based companion diagnostics that inform risk stratification and targeted therapy decisions. Nanostring Technologies and Biocartis (noted among leading companies lists) deliver digital spatial profiling and cartridge‑based molecular testing, respectively, enabling multiplexed biomarker analysis and decentralized testing models that suit oncology diagnostics. Guardant, Illumina, Thermo Fisher, Roche, Abbott, Siemens Healthineers, GE Healthcare, Danaher, Agilent, and Bio‑Rad collectively represent the market’s mix of large integrators, instrument and reagent suppliers, and specialty innovators that together span imaging, tissue pathology, molecular sequencing, liquid biopsy, and laboratory automation—key technologies shaping detection, monitoring, and precision treatment selection in cancer care.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer diagnostics market by geography and historical trend. The scope of the report extends to sizing of the cancer diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann‑La Roche (Roche) leads the cancer diagnostics market with an extensive portfolio spanning tissue diagnostics, molecular assays, next‑generation sequencing, and companion diagnostics, and its diagnostics division is a market cornerstone for oncology testing worldwide. Illumina anchors genomics‑based cancer diagnostics through high‑throughput next‑generation sequencing platforms that enable comprehensive tumor profiling and support many liquid biopsy and precision‑medicine workflows. Guardant Health is a leader in ctDNA liquid biopsy for non‑invasive tumor genomic profiling and monitoring, with products like Guardant360 that have advanced real‑time treatment selection and minimal‑residual‑disease assessment. Thermo Fisher Scientific supplies a broad range of oncology‑relevant instruments, reagents, and sequencing solutions that support clinical labs and biopharma across molecular diagnostics, NGS, and companion diagnostics. Abbott Laboratories contributes immunoassays, molecular diagnostics, and point‑of‑care testing for key cancer biomarkers, maintaining a strong presence in clinical screening and companion testing.
Siemens Healthineers and GE Healthcare are major imaging and diagnostic systems providers whose platforms—ranging from advanced PET/CT and MRI scanners to laboratory automation—are central to cancer detection, staging, and therapy monitoring in clinical practice. Danaher Corporation, through its diagnostics subsidiaries (including Beckman Coulter and Leica Biosystems), offers immunoassays, flow cytometry, histopathology instruments, and molecular platforms that address multiple oncology testing needs across hospital and reference labs. Roche‑competitor Agilent Technologies and Bio‑Rad Laboratories supply critical instrumentation and assays used in molecular oncology research and diagnostics: Agilent for genomic and proteomic analytical systems and Bio‑Rad for highly sensitive ddPCR and other molecular tools used in ctDNA and mutation detection workflows. Qiagen provides sample‑to‑answer molecular diagnostic kits, nucleic acid extraction technologies, and companion‑diagnostic assays that facilitate robust molecular testing pipelines for oncology patients.
Several specialized and emerging players round out the top ten by driving niche innovation and clinical translation in cancer diagnostics. Exact Sciences focuses on population screening and molecular assays for cancer detection, notably colorectal cancer screening tests that combine molecular markers with clinical workflows. Myriad Genetics develops hereditary cancer risk assays and gene‑based companion diagnostics that inform risk stratification and targeted therapy decisions. Nanostring Technologies and Biocartis (noted among leading companies lists) deliver digital spatial profiling and cartridge‑based molecular testing, respectively, enabling multiplexed biomarker analysis and decentralized testing models that suit oncology diagnostics. Guardant, Illumina, Thermo Fisher, Roche, Abbott, Siemens Healthineers, GE Healthcare, Danaher, Agilent, and Bio‑Rad collectively represent the market’s mix of large integrators, instrument and reagent suppliers, and specialty innovators that together span imaging, tissue pathology, molecular sequencing, liquid biopsy, and laboratory automation—key technologies shaping detection, monitoring, and precision treatment selection in cancer care.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.